<DOC>
	<DOCNO>NCT00847015</DOCNO>
	<brief_summary>The purpose study find use combination standard chemotherapy ( gemcitabine cisplatin ) plus new target pill ( sunitinib ) help shrink tumor undergo surgery bladder cancer .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Sunitinib ( GC-S ) Neoadjuvant Chemotherapy Patients With Muscle-Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm muscle invasive transitional cell carcinoma bladder MSKCC . Clinical stage T2T4a N0/X M0 disease . Medically appropriate candidate radical cystectomy per MSKCC attend urologic oncologist . Karnofsky Performance Status ≥ 70 % . Age ≥ 18 year age . Required Initial Laboratory Values : Absolute neutrophil count ≥ 1500 cells/mm3 Platelets ≥ 100,000 cells/mm3 Hemoglobin ≥ 9.0g/dL Bilirubin ≤ 1.5 upper limit normal ( ULN ) institution Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 x ULN institution Alkaline phosphatase ≤ 2.5 x ULN institution Serum creatinine ≤ 1.5 mg/dL Estimated glomerular filtration rate ≥ 60 ml/min/1.73m2 use CKDEPI equation : eGFR = 141 x min ( Scr/k , 1 ) x max ( Scr/k , 1 ) 1.209 x 0.993Age x 1.018 [ female ] x 1.159 [ black ] Scr serum creatinine , k 0.7 female 0.9 male , 0.329 female 0.411 male , min indicate minimum Scr/k 1 , max indicate maximum Scr/k 1 . If female childbearing potential , pregnancy test negative . Patients reproductive potential must use effective method avoid pregnancy duration trial . Prior systemic chemotherapy ( prior intravesical therapy allow ) Prior radiation therapy bladder Evidence NYHA functional class III IV heart disease . Serious intercurrent medical psychiatric illness , include serious active infection . Preexisting sensory grade 3 neuropathy Major surgery radiation therapy &lt; 4 week start study treatment . Concomitant use investigational drug Any follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism . Ongoing cardiac dysrhythmias NCI CTCAE Version 3.0 grade ≥ 2 . Prolonged QTc interval baseline EKG ( &gt; 450 msec male &gt; 470 msec female ) . Uncontrolled hypertension ( &gt; 150/100 mmHg despite optimal medical therapy ) . Preexisting thyroid abnormality , thyroid function test maintain normal range medication . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection . Concurrent treatment another clinical trial . Supportive care trial nontreatment trial , e.g . QOL , allow . Ongoing treatment therapeutic dos warfarin ( low dose warfarin 2 mg po daily thromboembolic prophylaxis allow ) . Pregnancy breastfeed . Patients must surgically sterile postmenopausal , must agree use effective contraception period therapy . The definition effective contraception base judgment principal investigator designate associate . Male patient must surgically sterile agree use effective contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bladder</keyword>
	<keyword>Urinary</keyword>
	<keyword>CISPLATIN</keyword>
	<keyword>GEMCITABINE</keyword>
	<keyword>SU011248 ( Sunitinib Malate )</keyword>
	<keyword>08-159</keyword>
</DOC>